BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 20027124)

  • 1. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
    Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
    J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
    Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
    Suehisa H; Toyooka S
    Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
    Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
    Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
    Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
    Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.
    Viallet J; Ayoub J; Rousseau P; Souhami L; Hohneker J; Shepherd F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):64-71; discussion 71-2. PubMed ID: 7973771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
    J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
    Gauthier I; Ding K; Winton T; Shepherd FA; Livingston R; Johnson DH; Rigas JR; Whitehead M; Graham B; Seymour L
    Lung Cancer; 2007 Mar; 55(3):357-63. PubMed ID: 17141357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.
    Sonobe M; Okubo K; Teramukai S; Yanagihara K; Sato M; Sato T; Chen F; Sato K; Fujinaga T; Shoji T; Omasa M; Sakai H; Miyahara R; Bando T; Date H
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1199-206. PubMed ID: 25253046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
    Arriagada R; Bergman B; Dunant A; Le Chevalier T; Pignon JP; Vansteenkiste J;
    N Engl J Med; 2004 Jan; 350(4):351-60. PubMed ID: 14736927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
    Sasidharan R; Gibbs D; Sullivan R; Simpson A; Perez D; Christmas T; McKeage M
    N Z Med J; 2006 Nov; 119(1245):U2310. PubMed ID: 17146485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
    Butts CA; Ding K; Seymour L; Twumasi-Ankrah P; Graham B; Gandara D; Johnson DH; Kesler KA; Green M; Vincent M; Cormier Y; Goss G; Findlay B; Johnston M; Tsao MS; Shepherd FA
    J Clin Oncol; 2010 Jan; 28(1):29-34. PubMed ID: 19933915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
    Pignon JP; Tribodet H; Scagliotti GV; Douillard JY; Shepherd FA; Stephens RJ; Dunant A; Torri V; Rosell R; Seymour L; Spiro SG; Rolland E; Fossati R; Aubert D; Ding K; Waller D; Le Chevalier T;
    J Clin Oncol; 2008 Jul; 26(21):3552-9. PubMed ID: 18506026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
    Kassam F; Shepherd FA; Johnston M; Visbal A; Feld R; Darling G; Keshavjee S; Pierre A; Waddell T; Leighl NB
    J Thorac Oncol; 2007 Jan; 2(1):39-43. PubMed ID: 17410008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.